CD8A and melanoma: In addition to the conventional biomarkers of TMB, neoantigen load and CD8+T-cell infiltration, a growing set of preclinical and clinical melanoma studies has provided valuable insights into novel TME-originated and blood-borne biomarkers that can predict response or resistance to immunotherapy.